Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg, of Actavis Laboratories FL, Inc.
According to IQVIA MAT July 2020 data, the US market for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg is approximately US$ 40 Mn. The product will be marketed by Strides Pharma Inc. in the US market.
The company has 126 cumulative ANDA filings with USFDA of which 91 ANDAs have been approved and 35 are pending approval.
Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.659.1 as compared to the previous close of Rs. 712.6. The total number of shares traded during the day was 157519 in over 3207 trades.
The stock hit an intraday high of Rs. 720 and intraday low of 654.95. The net turnover during the day was Rs. 109058267.